Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs

Neglected diseases represent a major health problem. It is estimated that one third of the world population is infected with tuberculosis (TB). Besides TB, Chagas disease, affects approximately 20 million people. Quinoxalines display great activities against TB and Chagas. Forty new quinoxaline 1,4-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ancizu, Saioa, Moreno, Elsa, Torres, Enrique, Burguete, Asunción, Pérez-Silanes, Silvia, Benítez, Diego, Villar, Raquel, Solano, Beatriz, Marín, Adoración, Aldana, Ignacio, Cerecetto, Hugo, González, Mercedes, Monge, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254273/
https://www.ncbi.nlm.nih.gov/pubmed/19553897
http://dx.doi.org/10.3390/molecules14062256
Descripción
Sumario:Neglected diseases represent a major health problem. It is estimated that one third of the world population is infected with tuberculosis (TB). Besides TB, Chagas disease, affects approximately 20 million people. Quinoxalines display great activities against TB and Chagas. Forty new quinoxaline 1,4-di-N-oxide derivatives have been prepared and tested against M. tuberculosis and T. cruzi. Carboxylic acid quinoxaline 1,4-di-N-oxides (CAQDOs) 5 and 17 showed MIC values on the same order as the reference antituberculosis drug, rifampicin. Meanwhile, CAQDOs 12 and 22 presented IC(50) values in the same order as the anti-chagasic drug, nifurtimox.

Ejemplares similares